Article ID: 5165-24
We herein report two cases of immunotactoid glomerulopathy (ITG) associated with multiple myeloma treated with daratumumab-based regimens. The first patient was an 81-year-old woman with severe renal insufficiency and IgAκ multiple myeloma (MM) that progressed to end-stage renal disease despite administering daratumumab-based therapy. The second patient, a 69-year-old man with smoldering MM, showed a favorable response to daratumumab-based treatment, with a resolution of nephrotic proteinuria. These cases underscore the association between hematological malignancies and ITG, while also emphasizing the need for clone-directed therapy. Although further accumulation of cases is needed, myeloma regimens, including daratumumab-based regimens, may be a beneficial treatment for ITG accompanied by plasma cell dyscrasia.
